<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>2026 Prices for Drugs That Are Subject to Negotiations | Khanh's feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.nytimes.com/2024/08/15/us/politics/drug-prices-medicare-negotiations.html">Original</a>
    <h1>2026 Prices for Drugs That Are Subject to Negotiations</h1>
    
    <div id="readability-page-1" class="page"><div id="site-content"><div><div id="in-story-masthead"><div><p><span><a href="https://www.nytimes.com/section/politics">Politics</a></span><span>|</span><span>2026 Prices for Drugs That Are Subject to Negotiations</span></p><div><p><span>https://www.nytimes.com/2024/08/15/us/politics/drug-prices-medicare-negotiations.html</span></p></div></div></div><article id="story"><header><p id="article-summary">The prices were made possible by the Inflation Reduction Act, which granted the health secretary the authority to negotiate on behalf of Medicare.</p><div><div><p><a href="https://www.nytimes.com/by/noah-weiland"><img alt="Noah Weiland" title="Noah Weiland" src="https://static01.nyt.com/images/2019/07/23/reader-center/author-noah-weiland/author-noah-weiland-thumbLarge.png"/></a><a href="https://www.nytimes.com/by/rebecca-robbins"><img alt="Rebecca Robbins" title="Rebecca Robbins" src="https://static01.nyt.com/images/2023/02/09/reader-center/author-rebecca-robbins/author-rebecca-robbins-thumbLarge.png"/></a></p></div></div><div data-testid="reading-time-module"><p><time datetime="2024-08-15T15:13:59-04:00"><span>Aug. 15, 2024</span><span>Updated <span>3:13 p.m. ET</span></span></time></p></div></header><section name="articleBody"><div><div><p>The Biden administration on Thursday <a href="https://www.nytimes.com/2024/08/15/us/politics/us-to-announce-prices-for-first-drugs-picked-for-medicare-negotiations.html" title="">announced the results</a> of negotiations between Medicare and pharmaceutical companies over the prices of 10 costly or common medications. The new prices, which will take effect in 2026, are the maximum Medicare Part D plans and patients will pay for a one-month supply.</p><p>It is impossible to tell how much the new prices will save Medicare for each individual drug. The federal government does not disclose the net prices it pays for medications, which take into account the billions of dollars in discounts that reduce Medicareâ€™s spending.</p><p>1. <strong>Eliquis</strong>, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231</p><p>2. <strong>Jardiance</strong>, for diabetes, heart failure and chronic kidney disease, from Boehringer Ingelheim and Eli Lilly, $197</p><p>3. <strong>Xarelto</strong>,<strong> </strong>for preventing strokes and blood clots, from Johnson &amp; Johnson, $197</p><p>4. <strong>Januvia</strong>, for diabetes, from Merck, $113</p><p>5. <strong>Farxiga</strong>, for diabetes, heart failure and chronic kidney disease, from AstraZeneca $178</p><p>6. <strong>Entresto</strong>, for heart failure, from Novartis, $295</p><p>7. <strong>Enbrel</strong>, for autoimmune conditions, from Amgen, $2,355</p><p>8. <strong>Imbruvica</strong>, for blood cancers, from AbbVie and Johnson &amp; Johnson, $9,319</p><p>9. <strong>Stelara</strong>, for autoimmune conditions, from Johnson &amp; Johnson, $4,695</p><p>10. <strong>Fiasp </strong>and<strong> NovoLog </strong>insulin products, for diabetes, from Novo Nordisk, $119</p></div></div></section><div><div><div><p>Rebecca Robbins is a reporter covering the pharmaceutical industry. She has been reporting on health and medicine since 2015.<span> <a href="https://www.nytimes.com/by/rebecca-robbins">More about Rebecca Robbins</a></span></p></div></div></div></article></div></div></div>
  </body>
</html>
